Literature DB >> 2873534

Reduced high-affinity glutamate uptake sites in the brains of patients with Huntington's disease.

A J Cross, P Slater, G P Reynolds.   

Abstract

The binding of D-[3H]aspartic acid to the high-affinity glutamate uptake system was studied in membrane preparations of postmortem brains from controls and Huntington's disease (HD) subjects. The groups were matched for age and postmortem delay. A large (60-72%) and significant reduction in D-[3H]aspartate binding was observed in both the caudate nucleus and putamen, but not in the frontal cortex of the HD brains. The loss of striatal D-[3H]aspartate binding may reflect a loss of the high-affinity glutamate uptake system contained on the terminals of corticostriatal afferents. In contrast, the binding of [3H]paroxetine to the serotonin uptake system was marginally increased in the caudate nucleus and unchanged in the putamen. It is suggested that the reduction of high-affinity glutamate uptake sites may contribute to the production of the striatal lesion in HD.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873534     DOI: 10.1016/0304-3940(86)90397-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

Review 1.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

2.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

3.  Neurotransmitter Release of Reprogrammed Cells Using Electrochemical Detection Methods.

Authors:  Andreas Heuer
Journal:  Methods Mol Biol       Date:  2021

4.  Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.

Authors:  Tara E Wood; Joshua Barry; Zhenquin Yang; Carlos Cepeda; Michael S Levine; Michelle Gray
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

5.  Neocortical neurotransmitter markers in Huntington's disease.

Authors:  S J Pearson; G P Reynolds
Journal:  J Neural Transm Gen Sect       Date:  1994

6.  Effects of NMDA receptor antagonists on passive avoidance learning and retrieval in rats and mice.

Authors:  N Venable; P H Kelly
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 7.  Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement.

Authors:  P M Beart; R D O'Shea
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

8.  Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.

Authors:  Geraldine T Petr; Laurel A Schultheis; Kayla C Hussey; Yan Sun; Janet M Dubinsky; Chiye Aoki; Paul A Rosenberg
Journal:  Eur J Neurosci       Date:  2013-04-16       Impact factor: 3.386

Review 9.  GLT-1: The elusive presynaptic glutamate transporter.

Authors:  Theresa S Rimmele; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2016-04-26       Impact factor: 3.921

Review 10.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.